Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder
- 1 August 2004
- journal article
- research article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 38 (8) , 602-612
Abstract
Objective: To assess from a health sector perspective the incremental cost-effectiveness of interventions for generalized anxiety disorder (cognitive behavioural therapy [CBT] and serotonin and noradrenaline reuptake inhibitors [SNRIs]) and panic disorder (CBT, selective serotonin reuptake inhibitors [SSRIs] and tricyclic antidepressants [TCAs]). Method: The health benefit is measured as a reduction in disability-adjusted life years (DALYs), based on effect size calculations from meta-analyses of randomised controlled trials. An assessment on second stage filters (‘equity’, ‘strength of evidence’, ‘feasibility’ and ‘acceptability to stakeholders’) is also undertaken to incorporate additional factors that impact on resource allocation decisions. Costs and benefits are calculated for a period of one year for the eligible population (prevalent cases of generalized anxiety disorder/panic disorder identified in the National Survey of Mental Health and Wellbeing, extrapolated to the Australian population in the year 2000 for those aged 18 years and older). Simulation modelling techniques are used to present 95% uncertainty intervals (UI) around the incremental cost-effectiveness ratios (ICERs). Results: Compared to current practice, CBT by a psychologist on a public salary is the most cost-effective intervention for both generalized anxiety disorder (A$6900/DALY saved; 95% UI A$4000 to A$12 000) and panic disorder (A$6800/DALY saved; 95% UI A$2900 to A$15 000). Cognitive behavioural therapy results in a greater total health benefit than the drug interventions for both anxiety disorders, although equity and feasibility concerns for CBT interventions are also greater. Conclusions: Cognitive behavioural therapy is the most effective and cost-effective intervention for generalized anxiety disorder and panic disorder. However, its implementation would require policy change to enable more widespread access to a sufficient number of trained therapists for the treatment of anxiety disorders.Keywords
This publication has 30 references indexed in Scilit:
- Australian and New Zealand Clinical Practice Guidelines for the Treatment of Panic Disorder and AgoraphobiaAustralian & New Zealand Journal of Psychiatry, 2003
- Efficacy of Venlafaxine Extended Release in Patients With Major Depressive Disorder and Comorbid Generalized Anxiety DisorderThe Journal of Clinical Psychiatry, 2001
- Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety DisorderThe British Journal of Psychiatry, 2001
- Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety DisorderJAMA, 2000
- Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety DisorderAmerican Journal of Psychiatry, 2000
- Efficacy, Safety, and Tolerability of Venlafaxine Extended Release and Buspirone in Outpatients With Generalized Anxiety DisorderThe Journal of Clinical Psychiatry, 1999
- Blocking the cycle of panic disorderPostgraduate Medicine, 1999
- A Meta-Analysis of the Effects of Venlafaxine on Anxiety Associated With DepressionJournal of Clinical Psychopharmacology, 1998
- Paroxetine efficacy in the treatment of generalized anxiety disorderActa Psychiatrica Scandinavica, 1997
- The natural history of anxiety disordersActa Psychiatrica Scandinavica, 1991